Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 22, 2025
Discovery & Translation
Science Spotlight: Bacterial payload delivery from nose to brain
BioCentury’s roundup of translational innovations also includes targeting MSH3 to slow repeat expansion in Huntington’s; plus AAVs for kidney and T cells
BioCentury | Feb 19, 2025
Management Tracks
Mehta named CMO, Greenberg CBO at Nura Bio
Plus: Shawnte Mitchell joins Olema as chief legal and updates from Loqus23, Pheast, Crafton, Eupraxia and more
BioCentury | Feb 7, 2025
Discovery & Translation
Science Spotlight: New protein degradation mechanism
BioCentury’s roundup of translational innovations also includes new insight into repeat expansion in Huntington’s and 10 new products
BioCentury | Dec 7, 2024
Data Byte
At $1B, PTC-Novartis deal ties record for cash up front
But partnership lands fourth on overall upfront payment
BioCentury | Dec 2, 2024
Deals
PTC adds $1B up front, ‘more muscle’ for Huntington program via Novartis deal
Biotech retains upside in licensing agreement for oral therapy derived from same splicing platform as SMA drug
BioCentury | Nov 26, 2024
Deals
Sarepta broadens pipeline via siRNA deal with Arrowhead, paying $825M up front
CEO Ingram sees “the one significant strategic transaction” to transform Sarepta’s future, while Arrowhead preps for first-ever launch
BioCentury | Nov 7, 2024
Discovery & Translation
Science Spotlight: Multi-epitope antivirals, metastatic transition, and more
BioCentury’s roundup of translational innovations also includes a study from Amgen and a newco spotlight
BioCentury | Oct 22, 2024
Deals
Pfizer deepens degrader footprint, Novartis taps China’s Baiyu, and more
Deals report: Pfizer-Triana to discover molecular glues; Novartis taps Baiyu for cancer small molecule; plus Ocean-Molecure, Takeda-Wave and more
BioCentury | Oct 17, 2024
Product Development
Wave data propel RNA-editing stocks, but are all platforms created equal?
In first human RNA-editing data, Wave reports positive results from WVE-006 in alpha-1 antitrypsin deficiency
BioCentury | Oct 10, 2024
Guest Commentary
We cannot continue to ignore heterogeneity in ALS
The tools exist, it’s time to embrace them. Long-read sequencing is just one of the force-multipliers at hand
Items per page:
1 - 10 of 199